Cardiol Therapeutics (CRDL) Income towards Parent Company (2020 - 2026)

Cardiol Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 21.58% year-over-year to -$6.9 million; the trailing twelve-month figure through Mar 2026 stood at -$19.9 million (up 8.55% YoY), and the FY2025 full-year result was -$24.1 million, up 13.91% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$6.9 million, up from -$7.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$4.7 million in Q2 2023, with the low at -$10.4 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$6.8 million across 5 years, with a median of -$6.5 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company surged 43.66% — and 2024, when it tumbled 81.51%.
• Cardiol Therapeutics' Income towards Parent Company stood at -$6.7 million in 2022, then increased by 14.77% to -$5.7 million in 2023, then plunged by 81.51% to -$10.4 million in 2024, then increased by 28.64% to -$7.4 million in 2025, then climbed by 6.29% to -$6.9 million in 2026.
• The last three Income towards Parent Company figures came in at -$6.9 million (Q1 2026), -$7.4 million (Q3 2025), and -$5.5 million (Q2 2025), per Business Quant data.